Media - Our stories

Explore our recent stories to see what drives us

10 January 2023

Acquisition of Crestor™

Acquisition of Crestor™

“Our M&A strategy is designed to enrich our portfolio of brands. We achieve this partly through the acquisition of established brands irrespective of the therapeutic area.”

Quentin Le Masne de Chermont

Head of Corporate Strategy and Portfolio Management

Grünenthal acquired the European rights (excluding Spain and the UK) to Crestor™ (rosuvastatin) from AstraZeneca in February 2021.

This product is a statin, also known as a lipid-lowering medicine. It blocks an enzyme in the liver from causing the liver to make less cholesterol, while it also increases the uptake and breakdown of cholesterol by the liver. Crestor™ is used to treat blood lipid disorders and prevent cardiovascular events like heart attacks and strokes, which are among the most burdensome diseases in Europe1.

Crestor™ is approved as a lipid-regulating medicine in more than 100 countries. With this agreement, Grünenthal acquired the exclusive rights to market Crestor™ and its second brands in more than 30 European markets. The company will also take over bulk production and packaging for the defined markets by 2025.

1 Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37: 3232-3245.


Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin) (PDF)

Grünenthal agrees to acquire European rights to CRESTOR™ (rosuvastatin) from AstraZeneca (PDF) 

Further details on our company can be found in our annual report.



Get in touch

We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.

Contact us


Share this story: